The phase III BEACON clinical trial made progress in the development of BRAF inhibitors by establishing combined encorafenib/cetuximab as a new standard of care for patients with BRAFV600E metastatic colorectal cancer who progressed to one or two previous lines of chemotherapy (3). Here, BRAF is linked to metastatic colorectal cancer.